

# Kim-Heang Ly

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6468790/kim-heang-ly-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29  
papers

556  
citations

15  
h-index

23  
g-index

32  
ext. papers

738  
ext. citations

5.1  
avg, IF

3.25  
L-index

#	Paper	IF	Citations
29	Pathogenesis of giant cell arteritis: More than just an inflammatory condition?. <i>Autoimmunity Reviews</i> , <b>2010</b> , 9, 635-45	13.6	88
28	Interleukin-1 blockade in refractory giant cell arteritis. <i>Joint Bone Spine</i> , <b>2014</b> , 81, 76-8	2.9	54
27	Cerebral abscesses in hereditary haemorrhagic telangiectasia: a clinical and microbiological evaluation. <i>Clinical Neurology and Neurosurgery</i> , <b>2012</b> , 114, 235-40	2	51
26	Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 1547-52	4.1	44
25	Involvement and prognosis value of CD8(+) T cells in giant cell arteritis. <i>Journal of Autoimmunity</i> , <b>2016</b> , 72, 73-83	15.5	37
24	Recovery of adrenal function after long-term glucocorticoid therapy for giant cell arteritis: a cohort study. <i>PLoS ONE</i> , <b>2013</b> , 8, e68713	3.7	34
23	Giant-cell arteritis: concordance study between aortic CT angiography and FDG-PET/CT in detection of large-vessel involvement. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> , 44, 2274-2279	8.8	32
22	Risk Factors for Permanent Visual Loss in Biopsy-proven Giant Cell Arteritis: A Study of 339 Patients. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 1393-9	4.1	30
21	Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study. <i>European Journal of Internal Medicine</i> , <b>2018</b> , 57, 96-104	3.9	20
20	Different patterns and specific outcomes of large-vessel involvements in giant cell arteritis. <i>Journal of Autoimmunity</i> , <b>2019</b> , 103, 102283	15.5	19
19	Steroid-sparing effect and toxicity of dapsone treatment in giant cell arteritis: A single-center, retrospective study of 70 patients. <i>Medicine (United States)</i> , <b>2016</b> , 95, e4974	1.8	18
18	Proteomic analysis of vascular smooth muscle cells in physiological condition and in pulmonary arterial hypertension: Toward contractile versus synthetic phenotypes. <i>Proteomics</i> , <b>2016</b> , 16, 2637-2649	4.8	18
17	Molecular analysis of vascular smooth muscle cells from patients with giant cell arteritis: Targeting endothelin-1 receptor to control proliferation. <i>Autoimmunity Reviews</i> , <b>2017</b> , 16, 398-406	13.6	17
16	Giant-Cell Arteritis: Do We Treat Patients with Large-Vessel Involvement Differently?. <i>American Journal of Medicine</i> , <b>2017</b> , 130, 992-995	2.4	17
15	Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY. <i>Orphanet Journal of Rare Diseases</i> , <b>2018</b> , 13, 127	4.2	15
14	Contribution of antiferritin antibodies to diagnosis of giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1269-70	2.4	12
13	Development of Giant Cell Arteritis after Treating Polymyalgia or Peripheral Arthritis: A Retrospective Case-control Study. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 678-685	4.1	8

12	Giant cell arteritis presenting as isolated inflammatory response and/or fever of unknown origin: a case-control study. <i>Clinical Rheumatology</i> , <b>2018</b> , 37, 3405-3410	3.9	7
11	Features and prognosis of giant cell arteritis in patients over 85 years of age: A case-control study. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 49, 288-295	5.3	6
10	Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis. <i>Clinical and Translational Immunology</i> , <b>2021</b> , 10, e1332	6.8	6
9	An uncommon case of dyspnea with unilateral laryngeal paralysis in acromegaly. <i>Auris Nasus Larynx</i> , <b>2016</b> , 43, 105-7	2.2	4
8	Venous thrombosis in patients with giant cell arteritis: Features and outcomes in a cohort study. <i>Joint Bone Spine</i> , <b>2017</b> , 84, 323-326	2.9	4
7	Vascular Presentation and Outcomes of Patients With Giant Cell Arteritis and Isolated Symptomatic Limb Involvement. <i>Journal of Clinical Rheumatology</i> , <b>2020</b> , 26, 248-254	1.1	3
6	Risk profiling for a refractory course of giant cell arteritis: The importance of age and body weight: "Risk profiling for GC resistance in GCA". <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 1252-1261	5.3	2
5	Steroid-sparing effect of anakinra in giant-cell arteritis: a case series with clinical, biological and iconographic long-term assessments. <i>Rheumatology</i> , <b>2021</b> ,	3.9	2
4	Diagnostic Value of 18F-FDG PET/CT vs. Chest-Abdomen-Pelvis CT Scan in Management of Patients with Fever of Unknown Origin, Inflammation of Unknown Origin or Episodic Fever of Unknown Origin: A Comparative Multicentre Prospective Study.. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11,	5.1	1
3	Cornea verticillata and acroparesthesia efficiently discriminate clusters of severity in Fabry disease. <i>PLoS ONE</i> , <b>2020</b> , 15, e0233460	3.7	1
2	Maladie thromboembolique veineuse et arthrite à cellules géantes : caractéristiques et résultats dans une étude de cohorte. <i>Revue Du Rhumatisme (Edition Française)</i> , <b>2018</b> , 85, 261-265	0.1	
1	Blocage de l'interleukine-1 dans la maladie de Horton réfractaire. <i>Revue Du Rhumatisme (Edition Française)</i> , <b>2013</b> , 80, 512-514	0.1	